Vaccitech have entered into a Phase 2a clinical trial collaboration agreement with Arbutus Biopharma Corporation to evaluate an innovative combination of their therapeutic technologies for the treatment of patients with chronic HBV infection

July 7, 2021

Stay up to date

Get the latest on cutting-edge developments in our portfolio, straight to your inbox.